zinc finger protein 446Genealiases: ZKSCAN20 · ZSCAN52
Q-omics provides the consensus-scored ZNF446 profile across patient tissues and cancer cell-line models. ZNF446 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ZNF446 is differentially expressed in 14, with the highest sampling consensus in LIHC. Additionally, ZNF446 RNA expression shows 19,644 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BRCA, LIHC, and ACC as cancer lineages where ZNF446 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF446 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF446 survival associations across molecular data types. ZNF446 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF446 RNA expression–survival associations across cancer types. High ZNF446 expression shows unfavorable associations in ACC, LGG, LIHC and DLBC, but favorable associations in BRCA and SCLC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for ZNF446 RNA expression.
This table summarizes ZNF446 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF446. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF446 shows lower tumor expression in KICH and higher tumor expression in LIHC, HNSC, COAD, BRCA and CHOL. The LIHC box plot shows higher ZNF446 RNA expression in tumor versus normal tissue (log2 FC = +0.968, t-test p < 0.001).
This table shows molecular features associated with ZNF446 in patient tissues and cancer cell lines. In patient samples, ZNF446 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF446 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
